Fischer Medical Ventures Expands Integrated Healthcare Technology Portfolio

FMVL's Preventive Healthcare business is being developed through FlynnCare, a wholly owned subsidiary focused on AI-enabled screening, diagnostics, and connected healthcare.

Fischer Medical Ventures (FMVL) has outlined the expansion of its healthcare technology portfolio across radiology, preventive healthcare, and wellness, with a focus on integrated medical imaging, AI-enabled screening and diagnostics, digital healthcare, molecular testing, and technology-enabled rehabilitation.

The company’s Radiology business, which remains its founding and largest segment, combines a portfolio spanning MRI, CT, X-ray, and digital mammography, alongside screening and interventional radiology solutions.

Its imaging portfolio includes the AURIX 0.35T open MRI, AURA 0.7T open MRI, MICA/MICA Smart and QUIN 1.5T MRI systems, NEONA neonatal MRI, CLARION CT systems, Navigator digital mammography and X-ray systems, as well as next-generation MRI platforms currently under development.

The company also offers the Medharanya Suite for intraoperative MRI and an intraoperative CT platform designed for real-time surgical guidance.

According to the company, its Preventive Healthcare business is being developed through FlynnCare, a wholly owned subsidiary focused on AI-enabled screening, diagnostics and connected healthcare.

FlynnCare's portfolio includes Clinics 2.0, MIDAS and LIVE Dx, unified through its ATLAS healthcare analytics platform.

The company's eHAP devices, including the Health Lounge and Health ATM 2.0, bring together multiple screening capabilities across areas such as eye health, oral health, breast and cervical cancer risk, cardiovascular and pulmonary screening, diabetes-related risks, women's wellness and mental and occupational wellness.

The LIVE Dx platform combines connected healthcare devices, AI-enabled analysis, remote monitoring, and telehealth capabilities.

It is designed to support screening and care delivery across community, institutional, workplace, and household settings, with referral pathways to higher levels of care.

FMVL is also expanding its point-of-care molecular diagnostics capabilities through FMV Prime, a tabletop qPCR platform designed for molecular testing outside conventional laboratory environments.

According to the company, FMV Prime can conduct tuberculosis and rifampicin-resistance testing from a tongue swab in a single run in under two hours. Its broader testing menu is reported to cover more than 200 infectious diseases.

The company’s portable laboratory portfolio also includes an AI-powered immunofluorescence analyser and Mini CubeLab, a robotic platform combining haematology, clinical chemistry, immunofluorescence and cell imaging.

Beyond diagnostics, FMVL is developing a new Wellness Solutions segment centred on an AI-powered Integrated Rehabilitation Center concept, bringing rehabilitation, preventive wellness, functional fitness, recovery, healthy ageing and longevity services together in a technology-enabled facility.

The proposed model uses AI as a decision-support tool while retaining qualified professionals as responsible for assessment, treatment decisions, and client safety. The company's proposed flagship format covers approximately 5,000 square feet across nine functional zones, with the first rollout planned for Malaysia and an ambition to establish 20 centres over two years.

In addition, it is also strengthening its molecular research capabilities by deepening its partnership to bring Vecura, an AI-enabled molecular research platform, to India.

The initiative is intended to support pharmaceutical companies, biotechnology innovators, academic institutions and research organisations in areas including computational biology, molecular analysis, target identification, compound screening and molecular optimisation.

Through the platform, the company seeks to explore the intersection of AI, computational biology and India's Ayurvedic knowledge aimed at supporting research into bioactive molecules and evidence-based therapeutics derived from traditional medicinal ingredients.

The expansion comes as FMVL continues to develop its international footprint across Southeast Asia and other markets, with commercial deployments in Southeast Asia, including Indonesia and the Philippines.

In Indonesia, the company entered the market in October 2024 with its 4T4TB, Trace, Test, Treat, Track solution, integrating portable digital X-ray systems, AI-assisted image analysis, and the FMV Prime qPCR molecular testing platform for tuberculosis screening and diagnosis. The company describes this engagement as its first significant commercial presence outside India.

Reflecting on the company’s evolution, R. Govindan, Executive Chairman and Managing Director, Fischer Medical Ventures said, “Fifteen years ago we set out to build advanced medical imaging in a country that had never made it, for the countries that cannot afford to import it. We did that, and we are now doing it in five countries at once.”

He added that “FMVL's proposition extends beyond medical imaging hardware, with its systems integrating software, artificial intelligence, cloud-based radiology, screening capabilities, and digital-health connectivity.”

Stay tuned for more such updates on Digital Health News